10 mg vials only $99

Note: This article is for educational and informational purposes only. Any studies referenced relate solely to laboratory and scientific models. Peptides discussed here are for Research Use Only. They are not approved drugs, supplements, or cosmetic products and are not for human or veterinary use.

Retatrutide and tirzepatide are two of the most closely watched compounds in modern obesity and metabolic research, but they do not work in exactly the same way. Tirzepatide activates two hormone receptors, GIP and GLP-1. Retatrutide activates those same receptors while adding a third target, the glucagon receptor.

That distinction makes tirzepatide a dual receptor agonist and retatrutide a triple receptor agonist.

Tirzepatide has already completed the regulatory approval process for chronic weight management, while retatrutide remains investigational. Recent Phase 3 retatrutide research has reported substantial reductions in body weight, increasing interest in how the two compounds compare.

There is an important limitation, however. Results from separate clinical trials cannot establish that one compound is definitively superior to the other. Differences in study populations, trial duration, protocols and statistical methods all need to be considered.

Retatrutide vs Tirzepatide: Quick Answer

The primary difference between retatrutide and tirzepatide is receptor activity. Tirzepatide targets GIP and GLP-1 receptors, while retatrutide targets GIP, GLP-1 and glucagon receptors. Tirzepatide is FDA approved and has a larger established clinical evidence base. Retatrutide remains investigational, but Phase 3 research has reported average weight reductions as high as 28.3% at 80 weeks with the 12 mg dose. Because those results come from separate trials, they do not prove that retatrutide is more effective than tirzepatide in a direct comparison.

Retatrutide vs Tirzepatide at a Glance

The percentages above come from separate clinical trials with different protocols, durations, participant populations and statistical methods. They should not be interpreted as a direct head-to-head comparison.

What Is Tirzepatide?

Tirzepatide is a dual GIP and GLP-1 receptor agonist developed by Eli Lilly.

GLP-1 signaling can influence appetite, glucose-dependent insulin secretion and gastric emptying. GIP also participates in glucose-dependent insulin signaling and nutrient metabolism. By activating both pathways, tirzepatide expanded on the single receptor approach used by earlier GLP-1 receptor agonists.

The Phase 3 SURMOUNT-1 trial published in the New England Journal of Medicine enrolled 2,539 adults with obesity or overweight and at least one weight-related complication, without diabetes.

Participants received tirzepatide or placebo for 72 weeks. Mean weight reduction was 15.0% with 5 mg tirzepatide, 19.5% with 10 mg and 20.9% with 15 mg, compared with 3.1% with placebo.

In November 2023, the FDA approved tirzepatide as Zepbound for chronic weight management in qualifying adults. Tirzepatide is also approved under the Mounjaro brand name for type 2 diabetes.

What Is Retatrutide?

Retatrutide is an investigational metabolic compound developed by Eli Lilly. It activates three receptor systems:

• GLP-1
• GIP
• Glucagon

The addition of glucagon receptor activity is the defining difference between retatrutide and tirzepatide.

Interest in the compound increased significantly following a Phase 2 retatrutide obesity trial published in the New England Journal of Medicine. That trial established evidence for the compound’s triple receptor mechanism and produced substantial reductions in body weight over 48 weeks.

Retatrutide subsequently moved into the Phase 3 TRIUMPH clinical development program.

In May 2026, Eli Lilly announced results from TRIUMPH-1, its pivotal Phase 3 obesity trial of retatrutide.

At 80 weeks, average weight reduction under the efficacy estimand was:

• 19.0% with 4 mg retatrutide
• 25.9% with 9 mg retatrutide
• 28.3% with 12 mg retatrutide

Participants with a baseline BMI of at least 35 who continued in a prespecified extension experienced an average reduction of 30.3% with 12 mg retatrutide at 104 weeks.

For a closer look at the doses and escalation schedules evaluated in clinical research, see Retatrutide Dosing: What the Research Says.

What Is the Main Difference Between Retatrutide and Tirzepatide?

The simplest difference is the number of receptors each compound activates.

Tirzepatide targets:

• GIP
• GLP-1

Retatrutide targets:

• GIP
• GLP-1
• Glucagon

The glucagon receptor is what makes retatrutide scientifically distinct from tirzepatide.

GLP-1 and GIP signaling can influence appetite, glucose regulation, insulin response and nutrient handling. Glucagon has additional metabolic actions involving energy mobilization and energy expenditure.

Researchers are therefore studying whether combining glucagon activity with GIP and GLP-1 signaling can influence several aspects of metabolic regulation simultaneously.

Activating an additional receptor does not automatically make a compound more effective. Researchers must evaluate receptor balance, clinical effectiveness, tolerability and long-term safety.

For more discussion of the three-receptor mechanism, see Retatrutide and Body Composition: How Is GLP-3 Different?.

Does Retatrutide Produce More Weight Loss Than Tirzepatide?

Based on results from separate clinical trials, retatrutide has produced a higher reported average percentage reduction in body weight at its highest studied dose than tirzepatide did in the original SURMOUNT-1 obesity trial.

In SURMOUNT-1, participants receiving 15 mg tirzepatide experienced an average weight reduction of 20.9% at 72 weeks.

In TRIUMPH-1, average weight reduction at 80 weeks reached 25.9% with 9 mg retatrutide and 28.3% with 12 mg.

Those numbers make retatrutide particularly interesting to metabolic researchers, but they need to be interpreted carefully.

SURMOUNT-1 and TRIUMPH-1 were separate studies. They enrolled different participants, lasted for different periods and used different protocols and statistical approaches.

The available evidence therefore supports the conclusion that retatrutide has produced substantial weight reduction in Phase 3 research. It does not establish that retatrutide would outperform tirzepatide if the two compounds were evaluated directly under identical trial conditions.

A randomized head-to-head trial would provide stronger evidence for answering that question.

Why Could Glucagon Receptor Activity Matter?

The glucagon receptor is the most important mechanistic difference between retatrutide and tirzepatide.

Glucagon is commonly associated with increasing blood glucose through the release of stored glucose from the liver. However, glucagon signaling also participates in energy expenditure, lipid metabolism and broader metabolic regulation.

Retatrutide combines this activity with GLP-1 and GIP receptor agonism.

Researchers are investigating whether coordinated signaling across these three pathways can influence energy expenditure while GLP-1 and GIP pathways contribute to appetite regulation, glucose control and nutrient metabolism.

This triple receptor design has also increased interest in how retatrutide may affect fat mass, lean tissue and overall body composition.

Our article on Retatrutide and Body Composition examines those questions in greater detail.

How Do Retatrutide and Tirzepatide Side Effects Compare?

Both compounds have commonly produced gastrointestinal adverse effects in clinical trials.

Reported effects include:

• Nausea
• Diarrhea
• Constipation
• Vomiting

In the SURMOUNT-1 tirzepatide trial, gastrointestinal events were the most commonly reported adverse events and generally occurred during dose escalation.

Retatrutide trials have also reported gastrointestinal adverse effects, with tolerability influenced by dose and escalation strategy.

The safety evidence for tirzepatide is currently more established because it has completed regulatory review and has accumulated considerably more clinical and real-world experience.

Retatrutide has a growing body of Phase 2 and Phase 3 safety data, but it remains investigational and does not yet have the same amount of long-term post-approval safety information.

For a more complete review of the available evidence, see Retatrutide Side Effects: Research, Safety, and Tolerability.

Is Retatrutide FDA Approved?

No.

As of September 2026, retatrutide remains investigational and has not been approved by the FDA. Eli Lilly continues to describe retatrutide as an investigational compound in its current information about the retatrutide clinical development program.

Tirzepatide, by comparison, has completed the regulatory process. The FDA approved Zepbound for chronic weight management in qualifying adults in 2023.

This difference in regulatory status is one of the most important distinctions between the compounds.

Which Has More Research, Retatrutide or Tirzepatide?

Tirzepatide currently has the more established evidence base.

It has completed numerous Phase 3 studies, undergone regulatory review and accumulated real-world clinical experience following approval.

Researchers also now have longer-term tirzepatide data. A long-term analysis of SURMOUNT-1 published in the New England Journal of Medicine followed participants with obesity and prediabetes receiving tirzepatide for 176 weeks.

Retatrutide has progressed rapidly through clinical development and has now generated substantial Phase 2 and Phase 3 evidence, but its clinical research history remains shorter.

This distinction is important when comparing the compounds. Early efficacy results can generate scientific interest, but regulatory review, longer-term follow-up and broader clinical experience provide additional information about safety and effectiveness.

Retatrutide vs Tirzepatide: What Does the Research Tell Us?

Tirzepatide demonstrated that targeting GIP and GLP-1 together could produce substantial metabolic effects.

Retatrutide is testing whether adding glucagon receptor activity can expand that approach further.

Current evidence shows:

• Both compounds activate GIP and GLP-1 receptors.
• Retatrutide additionally activates the glucagon receptor.
• Tirzepatide has extensive Phase 3 evidence, regulatory approval and real-world clinical experience.
• Retatrutide has produced substantial results in Phase 2 and Phase 3 research but remains investigational.
• Retatrutide has produced higher average weight reduction in some studies than the results reported in the original major tirzepatide obesity trial.
• Results from separate trials cannot establish that retatrutide is superior to tirzepatide in a direct comparison.

Rather than viewing the compounds only as competitors, they can also be viewed as part of the evolution of multi-receptor metabolic research.

GLP-1 receptor agonists established an important foundation. Tirzepatide expanded that approach by targeting GIP and GLP-1. Retatrutide is now testing what happens when glucagon receptor activity is added as a third pathway.

The Phase 3 results have made retatrutide one of the most closely watched investigational compounds in metabolic research. Its ultimate role will depend on the complete clinical development program, regulatory review and continued evaluation of long-term safety and efficacy.

Research References

• Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine.
  
• Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. New England Journal of Medicine.
  
• Eli Lilly and Company. TRIUMPH-1 Phase 3 Retatrutide Results.
  
• Eli Lilly and Company. TRIUMPH-1 Phase 3 Obesity Study Presented at the 2026 ADA Scientific Sessions.
  
• U.S. Food and Drug Administration. FDA Approves Tirzepatide for Chronic Weight Management.
  
• Jastreboff AM, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. New England Journal of Medicine.
  
• Eli Lilly and Company. What to Know About Retatrutide.